Atossa Therapeutics shares rise 12.36% intraday after receiving positive FDA feedback for (Z)-endoxifen dose optimization trial.

Atossa Therapeutics, Inc. rose 12.36% intraday, driven by positive news from the U.S. Food and Drug Administration (FDA) regarding the company's proposed dose optimization trial of (Z)-endoxifen for the treatment of estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. The FDA provided constructive feedback, affirming key elements of Atossa's clinical development plan and negating the need for a virtual meeting, which paved the way for a potential Investigational New Drug (IND) application.